LAVA Medtech Acquisition closed its IPO of 11.5 million units at $10 per unit, including 1.5 million issued pursuant to the full exercise of the underwriters’ over-allotment option.
Units trade on the Nasdaq under LVACU.
The SPAC’s acquisition focus is on companies within the healthcare and healthcare-related industries, primarily in the United States and Canada.
RBC Capital Markets served as the sole book-running manager of the offering. Read more.
